Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z2GF
|
||||
| Former ID |
DIB003126
|
||||
| Drug Name |
NI-101
|
||||
| Synonyms |
BART; Ch12F6A; BIIB-037; MAb (AD), Neurimmune/Biogen Idec; Monoclonal antibodies (Alzheimer!?s disease), Neurimmune Therapeutics/Biogen Idec; Anti-beta amyloid mAbs (Alzheimer!?s disease), Neurimmune Therapeutics/Biogen Idec
|
||||
| Drug Type |
Antibody
|
||||
| Company |
Neurimmune Therapeutics AG
|
||||
| Target and Pathway | |||||
| Target(s) | Amyloid beta A4 protein | Target Info | [544353] | ||
| KEGG Pathway | Notch signaling pathway | ||||
| Alzheimer's disease | |||||
| Reactome | Nuclear signaling by ERBB4 | ||||
| Degradation of the extracellular matrix | |||||
| Regulated proteolysis of p75NTR | |||||
| NRIF signals cell death from the nucleus | |||||
| Activated NOTCH1 Transmits Signal to the Nucleus | |||||
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||||
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||||
| EPH-ephrin mediated repulsion of cells | |||||
| References | |||||
| Ref 525246 | ClinicalTrials.gov (NCT02484547) 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease. | ||||
| Ref 543075 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8325). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.